ES2358193T3 - Un proceso para la preparación de 5-(haloacetil)-8-(oxi sustituido)-(1h)-quinolin-2-onas. - Google Patents

Un proceso para la preparación de 5-(haloacetil)-8-(oxi sustituido)-(1h)-quinolin-2-onas. Download PDF

Info

Publication number
ES2358193T3
ES2358193T3 ES04725035T ES04725035T ES2358193T3 ES 2358193 T3 ES2358193 T3 ES 2358193T3 ES 04725035 T ES04725035 T ES 04725035T ES 04725035 T ES04725035 T ES 04725035T ES 2358193 T3 ES2358193 T3 ES 2358193T3
Authority
ES
Spain
Prior art keywords
quinolin
hydroxy
substituted
oxy
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04725035T
Other languages
English (en)
Spanish (es)
Inventor
Olivier Lohse
Gerhard Penn
Hanspeter Schilling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33131902&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2358193(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Application granted granted Critical
Publication of ES2358193T3 publication Critical patent/ES2358193T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
ES04725035T 2003-04-02 2004-04-01 Un proceso para la preparación de 5-(haloacetil)-8-(oxi sustituido)-(1h)-quinolin-2-onas. Expired - Lifetime ES2358193T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45972403P 2003-04-02 2003-04-02
US459724P 2003-04-02

Publications (1)

Publication Number Publication Date
ES2358193T3 true ES2358193T3 (es) 2011-05-06

Family

ID=33131902

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04725035T Expired - Lifetime ES2358193T3 (es) 2003-04-02 2004-04-01 Un proceso para la preparación de 5-(haloacetil)-8-(oxi sustituido)-(1h)-quinolin-2-onas.

Country Status (34)

Country Link
US (1) US7605267B2 (fr)
EP (1) EP1613599B8 (fr)
JP (1) JP4726778B2 (fr)
KR (1) KR101073740B1 (fr)
CN (1) CN1774423A (fr)
AR (2) AR043825A1 (fr)
AT (1) ATE491690T1 (fr)
AU (1) AU2004226212B2 (fr)
BR (1) BRPI0409154B1 (fr)
CA (1) CA2520990C (fr)
CL (1) CL2004000706A1 (fr)
CO (1) CO5700779A2 (fr)
CY (1) CY1111515T1 (fr)
DE (1) DE602004030553D1 (fr)
DK (1) DK1613599T3 (fr)
EC (1) ECSP056059A (fr)
ES (1) ES2358193T3 (fr)
HR (1) HRP20110184T1 (fr)
IL (1) IL171053A (fr)
IS (1) IS2800B (fr)
MA (1) MA27761A1 (fr)
MX (1) MXPA05010616A (fr)
MY (1) MY141871A (fr)
NO (1) NO331980B1 (fr)
NZ (1) NZ542623A (fr)
PE (2) PE20100399A1 (fr)
PL (1) PL1613599T3 (fr)
PT (1) PT1613599E (fr)
RU (1) RU2339621C2 (fr)
SI (1) SI1613599T1 (fr)
TN (1) TNSN05245A1 (fr)
TW (1) TWI324151B (fr)
WO (1) WO2004087668A1 (fr)
ZA (1) ZA200507603B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) * 2004-06-22 2004-07-28 Novartis Ag Organic compounds
DK2044025T3 (da) 2006-06-30 2013-01-14 Novartis Ag Quinolinonderivater samt farmaceutiske sammensætninger deraf
WO2013132514A2 (fr) * 2012-03-09 2013-09-12 Rao Davuluri Ramamohan Nouveau procédé de préparation de (r)-5-[2-[(5, 6-diéthyl-2, 3-dihydro-1h-indèn-2-yl) amino]-1-hydroxyéthyl]-8-hydroxy quinoléin-2(1h)-one
CN102633717B (zh) * 2012-03-30 2013-11-20 西南大学 N-乙酰-喹啉-2(1h)酮类化合物及其制备方法和应用
WO2014008640A1 (fr) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 Intermédiaire d'indacatérol et procédé de synthèse d'indacatérol
CZ306252B6 (cs) 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
ES2815123T3 (es) 2014-01-09 2021-03-29 Davuluri Ramamohan Rao Proceso novedoso para la preparación de indacaterol o sus sales aceptables farmacéuticamente
CN105693603B (zh) * 2014-11-24 2019-11-29 上海医药工业研究院 改良的马来酸茚达特罗制备工艺
WO2016161956A1 (fr) * 2015-04-09 2016-10-13 正大天晴药业集团股份有限公司 Procédé de préparation d'indacatérol ou du sel de celui-ci
CN107868045A (zh) * 2016-09-28 2018-04-03 四川海思科制药有限公司 一种茚达特罗中间体的制备方法
CN108264483A (zh) * 2016-12-31 2018-07-10 天津金耀集团有限公司 一种马来酸茚达特罗的制备方法
CN109721534B (zh) * 2018-09-25 2022-05-20 四川海思科制药有限公司 一种马来酸茚达特罗中间体及其制备方法和用途
CN114751857A (zh) * 2022-04-29 2022-07-15 梯尔希（南京）药物研发有限公司 一种茚达特罗杂质的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS539228B2 (fr) * 1974-01-31 1978-04-04
CA1164459A (fr) 1980-11-11 1984-03-27 Yung-Hsiung Yang Methode de preparation de (imidozo¬1,2-a| pyridine-2-yl)-carbostyrile ou de deries-3,4- dihydrocarbostyrile
JPS5896022A (ja) * 1981-11-30 1983-06-07 Otsuka Pharmaceut Co Ltd 強心剤
ES8403457A1 (es) * 1983-01-28 1984-03-16 Espanola Farma Therapeut Procedimiento para la obtencion de un compuesto derivado de la 2-quinolinona.
ES8605239A1 (es) * 1985-12-04 1986-03-16 Astur Pharma Un procedimiento para la preparacion de quinolonas sustitui-das
US4894219A (en) * 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
GB9405019D0 (en) * 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
NZ332341A (en) * 1996-05-20 2000-05-26 Darwin Discovery Ltd Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI324150B (en) * 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt

Also Published As

Publication number Publication date
PE20050211A1 (es) 2005-04-27
KR20050119678A (ko) 2005-12-21
TWI324151B (en) 2010-05-01
WO2004087668A1 (fr) 2004-10-14
US20060189653A1 (en) 2006-08-24
MXPA05010616A (es) 2005-11-23
ATE491690T1 (de) 2011-01-15
DK1613599T3 (da) 2011-03-28
JP4726778B2 (ja) 2011-07-20
DE602004030553D1 (de) 2011-01-27
MA27761A1 (fr) 2006-02-01
IL171053A (en) 2010-12-30
BRPI0409154A (pt) 2006-03-28
EP1613599B8 (fr) 2011-06-22
CN1774423A (zh) 2006-05-17
NO20055099D0 (no) 2005-11-01
CL2004000706A1 (es) 2005-01-14
CA2520990C (fr) 2011-08-09
JP2006522055A (ja) 2006-09-28
AR043825A1 (es) 2005-08-17
SI1613599T1 (sl) 2011-04-29
AU2004226212B2 (en) 2008-02-21
EP1613599B1 (fr) 2010-12-15
PE20100399A1 (es) 2010-06-01
CO5700779A2 (es) 2006-11-30
NO20055099L (no) 2006-01-02
KR101073740B1 (ko) 2011-10-13
NZ542623A (en) 2008-07-31
HRP20110184T1 (hr) 2011-04-30
NO331980B1 (no) 2012-05-21
ZA200507603B (en) 2006-11-29
PL1613599T3 (pl) 2011-05-31
PT1613599E (pt) 2011-03-17
TW200504025A (en) 2005-02-01
MY141871A (en) 2010-07-16
US7605267B2 (en) 2009-10-20
AR103508A2 (es) 2017-05-17
CY1111515T1 (el) 2015-08-05
HK1086833A1 (en) 2006-09-29
CA2520990A1 (fr) 2004-10-14
EP1613599A1 (fr) 2006-01-11
IS2800B (is) 2012-09-15
BRPI0409154B1 (pt) 2014-03-25
IS8095A (is) 2005-10-27
AU2004226212A1 (en) 2004-10-14
ECSP056059A (es) 2006-01-27
TNSN05245A1 (en) 2007-06-11
RU2339621C2 (ru) 2008-11-27

Similar Documents

Publication Publication Date Title
ES2337273T3 (es) Preparacion enantioselectiva de derivados de quinolina.
ES2326974T3 (es) Proceso para preparar sales de 5-((r)-2-(5,6-dietil-indan-2-ilamino)-1-hidroxi-etil)-8-hidroxi-(1h)-quinolin-2-ona, utiles como agonistas adrenoceptores.
RU2339621C2 (ru) Способ получения 5-(альфа-галогенацетил)-8-(замещенный окси)-(1н)-хинолин-2-онов
HK1086833B (en) A process for the preparation of 5-(haloacetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones
HK1105121B (en) Enantioselective preparation of quinoline derivatives
HK1086255B (en) Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salts, useful as adrenoceptor agonists